Amgen, Inc. (AMGN) stock is up 2.00% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.
Amgen, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AMGN!
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With AMGN Stock Today?
Amgen, Inc. (AMGN) stock is trading at $270.78 as of 3:31 PM on Friday, Dec 1, a gain of $1.14, or 0.42% from the previous closing price of $269.64. Volume today is below average. So far 1,032,174 shares have traded compared to average volume of 2,367,364 shares. The stock has traded between $267.62 and $271.17 so far today.
To see InvestorsObserver's Sentiment Score for Amgen, Inc. click here.
More About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Click Here to get the full Stock Report for Amgen, Inc. stock.